Company profile

Shenzhen Forward Pharmaceuticals Co., Ltd.

Privately held: no public share price (Shenzhen (Nanshan)-based Chinese biotech founded 2015, developer of FWD1802, the compound named in its associated NCT trials; angel/Series A+ funded per EqualOcean/PitchBook, no stock listing or ticker found anywhere. Sources: https://clinicaltrials.gov/study/NCT06064812 ; https://api.gleif.org/api/v1/lei-records/984500G84CRC0D4B3920 ; https://api.gleif.org/api/v1/lei-records/984500CE07P48BCA4D79 ; https://equalocean.com/news/2023072819987 ; http://forward-pharm.com/about.html Entity resolved by asset-pipeline-v2.)

Assets

(1 total)

1Total Assets

0Approved

0Phase 3 / Filed

1Phase 1–2 / Early

1Diseases

Showing 1 of 1 assets

		Target & Modality
FWD1802	Phase 2	Estrogen receptor (degrader)Small molecule	HR+/HER2- Breast Cancer HR+/HER2- Metastatic Breast Cancer

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.